FR-β expression was evaluated in regard to known risk factors in ovarian cancer; e.g. grade of differentiation, FIGO stage, histological subtype (serous vs. non-serous), age (<58 vs. ≥58) and residual disease ≥2 cm. The gene discussed is FOLR2; the disease is ovarian carcinoma.